Hold BMY with 10 EMA warning at $66.19 and 50 SMA exit at $60.84; dividend carry and defensive floor outweigh technical yellow flags
Hold BMY at current position weight. The five consecutive BMY decision pattern in this cycle demonstrates that half-conviction Underweight produces marginal-to-negative alpha while forfeiting the 3.75% dividend carry—Hold calls generated +2.2% and +0.7% alpha with zero execution friction, while Underweight calls produced inconsistent outcomes of -2.3%, +1.9%, and +0.6%. The MACD divergence, RSI rollover, and ATR expansion are yellow flags (momentum slowing, not reversing) with absorption behavior evident in the Aug 3 shakeout recovery. The 0.225 beta, 2.54x FCF dividend coverage, $12-14B annual FCF, and intact 50/200 SMA structure constitute a thick structural floor that argues against full exit. The trader's 25-40% trim proposal replicates the 8/20 mistake at a marginally higher price. Anchor invalidation at 10 EMA ($66.19) close basis with hard exit at 50 SMA ($60.84); re-engage only on pullback to $60-62 zone with momentum reset or breakout above $68.10 with volume confirmation. Catalyst clock (Eliquis LOE late 2026) hasn't started ticking, making premature Underweight positioning suboptimal.
| Position | Action |
|---|---|
| Current position weight | Maintain (do not reduce) |
| Price at $67.92 | Do NOT add (11.6% above 50 SMA is overextension) |
| Trader's 25-40% trim proposal | Do NOT execute (forfeits dividend carry with no incremental alpha benefit) |
| Conservative analyst's 10% trim | Overstates risk—structural floor and 2.54x FCF dividend coverage argue against reduction |
| Close below 10 EMA ($66.19) | First warning signal—momentum may be shifting, begin monitoring |
| Close below 50 SMA ($60.84) | Hard exit—structural trend break, not noise tolerance |
BMY offers a dominant risk-adjusted opportunity as a defensive compounder with simultaneous growth re-rating potential, combining a 3.75%+ dividend yield, utilities-level beta (0.225), and a credible multi-billion dollar Cobenfy franchise expansion—all at a forward PE of just 10.36x.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $66.19 | bullish |
| 50 SMA | $60.84 | bullish |
| 200 SMA | $56.46 | bullish |
| RSI (14) | 65.30 | bullish |
| MACD Line | 1.68 | bullish |
| MACD Signal | 1.60 | bullish |
| MACD Histogram | +0.09 | neutral |
| Bollinger Middle (20 SMA) | $65.19 | neutral |
| Bollinger Upper | $68.01 | bearish |
| Bollinger Lower | $62.36 | bullish |
| ATR (14) | $1.73 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close above $68.10 on >13M shares with MACD re-acceleration
Then: Alternative re-engagement trigger
Riding the upper Bollinger Band during a sustained uptrend is normal behavior, not an exhaustion signal. MACD remains positive at +0.09 and RSI at 65.30 is bullish-but-not-overbought with no bearish divergence.
EV: +5.7% · concedes: TTM EPS of $4.54 is artificially compressed by acquisition-related charges from Karuna deal and intangible amortization; PEG ratio of 2.37 appears elevated on surface; Price is hugging the upper Bollinger Band at $68.01; MACD histogram compressing from 0.21 to 0.09 suggests momentum is pausing; Eliquis and Revlimid face eventual patent cliffs
BMY at $67.92 is a momentum chase priced for flawless Cobenfy execution against a $12B Eliquis patent cliff, with rising ATR, MACD divergence, depleting cash buffers, and $5-10B in goodwill impairment risk creating asymmetric downside — evidenced by the bull's own recommended entry zone sitting 2.5% below current levels.
· concedes: Net Debt/EBITDA of 1.82x is investment-grade range (though metric is moving in wrong direction as cash drains); Gross margin of 71.7% is elite pharma economics (though gross margin doesn't prevent revenue erosion); 200 SMA is rising (though lagging price by ~50%); Institutional news flow is constructive (though strongest single institutional piece this week picked PFE over BMY)
→ vs conservative: Moving average stack structure (10 EMA 66.19, 50 SMA 60.84, 200 SMA 56.46) is bullish but price is 11.6% above 50 SMA and 20.3% above 200 SMA—these are overextended levels, not healthy structure
→ vs conservative: August 3rd flush from 68.10 to 64.14 on 33M shares was not a one-time event but the volatility regime announcing itself; ATR has expanded further with wider shakeouts now at higher prices
→ vs conservative: 62% rally on 5.7% revenue growth is multiple expansion disconnected from fundamentals; PEG ratio of 2.37 prices a defensive name like a growth stock
→ vs conservative: Don't fight the trend is exit liquidity thinking—aggressive risk management trims into strength and positions for cleaner re-entry
→ vs neutral: Defensive pharma bid and macro support matter when buying at support, not holding at upper Bollinger Band after 62% rally
→ vs neutral: Higher-for-longer rates create multiple floor for dividend pharma when buying, not when 23% above 200-day moving average
→ vs neutral: Waiting for confirmation means giving back 8-12% chasing the exit; confirmation comes on the other side of the move
→ vs neutral: FCF cannot cover dividend—757 million FCF versus 1.28 billion dividends in Q1 2026 is a coverage problem that doesn't resolve itself without equity holders absorbing the concession
| neutral |
| VWMA | $65.36 | bullish |
| Price Close | $67.92 | bullish |
Support: 62.36 · 63 · 65.19 · 66.19 | Resistance: 68.01 · 68.1 · 70
BMY exhibits a strong bullish trend with price at $67.92, extended near the upper Bollinger Band ($68.01). Moving averages are stacked favorably (10 EMA $66.19 > 50 SMA $60.84 > 200 SMA $56.46), and RSI (65.30) remains in bullish territory without triggering overbought. MACD histogram compression (+0.09, down from 0.21) signals slowing momentum—a yellow flag rather than a reversal. ATR has risen to $1.73, indicating elevated volatility. Primary strategy: BUY on pullback to $65.20–$66.20 zone (3:1 risk/reward) or HOLD existing longs with trailing stops at $66.19 (10 EMA). Avoid entering at current extended levels near the upper band.
Market Capitalization
$138.74 billion
PE Ratio (TTM)
14.96
Forward PE
10.36
PEG Ratio
2.37
Price-to-Book
6.22
EPS (TTM)
$4.54
Forward EPS
$6.56
Dividend Yield
3.75%
Beta
0.225
52-Week High
$68.64
52-Week Low
$42.52
TTM Revenue
$49.19 billion
TTM Net Income
$9.28 billion
TTM EBITDA
$18.93B
TTM Gross Margin
71.7%
TTM Operating Margin
34.4%
TTM Net Profit Margin
18.87%
Return on Equity (ROE)
46.6%
Return on Assets (ROA)
10.7%
Total Assets
$87.63B
Total Debt
$45.05B
Net Debt
$34.40B
Stockholders Equity
$22.32B
Goodwill & Intangibles
$39.37B
Current Ratio
1.53
Net Debt / EBITDA
1.82x
Free Cash Flow (TTM)
$8.11B
Annualized Dividend
$5.10B
FCF/Dividend Coverage
1.59x
Q2 2026 Revenue
$12.97B
Q2 2026 Net Income
$3.317 billion
Q2 2026 Diluted EPS
$1.62
Q2 2026 Operating Margin
31.0%
Q2 2025 Diluted EPS
$0.64
Q1 2026 FCF
$757 million
Q2 2026 FCF
$3.09B
Debt Paydown (Q3 2025 to Q2 2026)
$6B
Goodwill
$21.74B
Intangibles (Q2 2026)
$17.63B
Tangible Book Value
-$17.05B
50-Day Moving Average
$60.78
200-Day Moving Average
$57.25
Strengths
Concerns
BMY presents a mixed investment opportunity with compelling Q2 2026 operational improvements including 31% operating margins, $3.09B FCF, and 153% YoY EPS growth, balanced against significant structural challenges. The company's aggressive deleveraging trajectory (reduced debt by $6B in three quarters) and Karuna acquisition are positive, but patent cliffs on key drugs (Eliquis, Revlimid) and elevated goodwill/intangibles represent material risks. At Forward PE of 10.36x with 3.75% dividend yield, the stock offers value for income-focused investors, but technical resistance at $68.64 and the 2.37 PEG ratio suggest limited upside at current levels.
Macro: Fed funds path: 0% cuts priced for 2026 (86% no-cut probability, +1.2pp WoW per Polymarket). US recession probability: 8% (+1pp WoW). 'Higher-for-longer' rates regime supportive for dividend-paying pharma (BMY yields ~5%+). Soft-landing narrative intact with 92% no-recession probability. Consumer discretionary weakness (Walmart '37-times valuation,' Target 'hit its top,' Nike punished) reinforces defensive rotation into pharma. Pharma M&A tone: WSJ 'never shop hungry' framing positions BMY as a logical BD target given LOE pressure on Eliquis and Opdivo.